Navigation Links
Empire Genomics Chooses Funakoshi as Japan Distributor
Date:4/24/2012

BUFFALO, N.Y., April 24, 2012 /PRNewswire-iReach/ -- Empire Genomics today announced that it has chosen Funakoshi as a distributor of its product portfolio for the Japanese market.  The deal represents Empire's international expansion and importance of growth in the region.

"We are excited to have such a proven and expert partner in Funakoshi to service our Japanese customers and offer access to our broad genomic product and service portfolio," said Anthony Johnson, President and CEO of Empire Genomics. "I am confident this relationship will provide customers with the excellent support and high quality service  our customers have come to expect."   

"We are delighted with Empire Genomics agreement. Empire Genomics perfectly complements our portfolio range of high quality products and services. Empire Genomics portfolio provides Funakoshi Company the opportunity to meet high demands for basic bioscience research and also for the pharmaceutical research in Japan." said Dr.Ryoya Funakoshi, President & CEO of Funakoshi Company, Ltd.

Financial terms of the deal were not disclosed.

About Empire Genomics, LLC

Empire Genomics delivers the most advanced genomic tools to aid the scientific community in its research and diagnostic challenges. Through many years of experience in the area of  genomics and working with diverse sample types, we are able to provide continuous innovation for research and diagnostic applications in areas of oncology, biomarkers, drug discovery, constitutional disorders, developmental disorders and autism, among many others.

About Funakoshi Co. Ltd.

Funakoshi Co., Ltd. has contributed as a leader to distribute research reagents and instruments for researchers in life science fields since its foundation. The mission of Funakoshi is offering many useful tools with leading edge technologies for Japanese researchers from all over the world to support and develop their research. For more information, visit Funakoshi's website: www.funakoshi.co.jp.

Media Contact:

Sonya Stutts Empire Genomics, LLC, 716-856-3873, sonya.stutts@empiregenomics.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Empire Genomics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Alert -- Empire Asset Management Co. Initiates Coverage on Pacira Pharmaceuticals Inc. (NASDAQ: PCRX)
2. Empire BlueCross BlueShield Expands Lab Networks -- Creating Broader Choice, Robust Competition and Lower Costs for Consumers
3. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
4. Everist Genomics Develops Worlds First Comprehensive Companion Diagnostics and Prognostics Portfolio for Early Diagnosis and Improved Treatment of Colorectal Cancer
5. Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
6. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
7. Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology
8. Smartphone Technology Meets Personalized Medicine in Everist Genomics CardioDefender Diagnostic System
9. AccuGenomics to Attend OneMedForum with Standardized Gene Expression Tests for Leukemia and Lung Cancer
10. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
11. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):